Skip to main content
OpenTrials
Completed

NCT Number: NCT04070664

Thiol/Disulphide Homeostasis and Albumin in Vertigo

Vertigo is a common complaint in the Emergency Department (ED). The differential diagnosis of central and peripheral vertigo is a difficult issue that directly affects mortality. Magnetic resonance imaging (MRI) is the preferred diagnostic tool, but may not be suitable in all patients due to logistic and economic conditions. In this study, the investigators evaluated the role of thiol/disulfide homeostasis (TDH) parameters and ischemia modified albumin (IMA) levels to assist in the value of being used instead of MRI.

Completed

Looking for future studies?

Notify Me

Key information

Age range

51 year–85 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Ankara Yıldırım Beyazıt University, School of Medicine, Department of Emergency Medicine

Ankara, Çankaya, 06800, Turkey (Türkiye)

About this study

The study was conducted in the ED using a prospective, non-randomized method, and included patients with complaints of acute onset vertigo over 18 years of age and who underwent brain MRI. Pregnant women, smokers, and those with significant neurological signs were excluded. Patients with acute ischemia with MRI were included in the central vertigo group, and patients with normal MRI were included in the peripheral vertigo group. Blood samples for native thiol (NT), total thiol (TT), disulfide, and IMA were collected from all patients at admission. Statistical analyzes were performed with IBM SPSS Statistics for Windows 16.0 Package Program.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with complaint of vertigo
  • Patients over18 years of age

Exclusion criteria

  • Patients contraindicated for MRI due to metal prosthesis or claustrophobia
  • Patients under 18 years of age
  • Pregnant patients
  • Tobacco users
  • Patients exhibiting significant neurological signs or symptoms such as motor or sensory neurologic deficit, speech disorders, unconsciousness, or seizure
  • Patients found to have any type of lesion such as a hematoma, mass, cyst, aneurysm, arteriovenous malformation, etc. other than ischemic infarcts on MRI
  • Patients with an ischemic lesion other than posterior fossa lesions
  • Patients with any type of infection, including upper respiratory tract and ear infections
  • Patients previously diagnosed with peripheral vertigo
  • Patients where the cause of lightheadedness was blood pressure disorders, cardiac ischemic and arrhythmic disorders, thromboembolic diseases, metabolic disorders, trauma, etc. rather than central and peripheral vertigo.

Treatment and study plan

Primary outcomes

  1. Oxidative stress

    Time frame: 6 months

    Thiol/disulphide homeostasis

  2. Ischemic status

    Time frame: 6 months

    Ischemia modified albumin

Sponsors and collaborators

Lead sponsor

Ankara City Hospital Bilkent

Other

Collaborators

  • Ankara Training and Research Hospital

Registry information

Official study title

Evaluation of Thiol/Disulfide Homeostasis and Ischemia Modified Albumin Levels in the Differential Diagnosis of Central and Peripheral Vertigo

Important dates

Study start
2018
Primary completion
2018
Study completion
2018
First posted
Aug 28, 2019
Registry last updated
Aug 28, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.